Cargando…

Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis

BACKGROUND: Trastuzumab is currently the standard treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, it is not recommended for HER2-positive breast cancer patients during pregnancy as it may jeopardize safety of the fetus. Nevertheless, there is evidence t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Lin-Yu, Hu, Qing-Lin, Zhou, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061001/ https://www.ncbi.nlm.nih.gov/pubmed/33882925 http://dx.doi.org/10.1186/s12905-021-01301-9

Ejemplares similares

Efficacy and Safety of Radiofrequency Ablation for Breast Cancer Smaller Than 2 cm: A Systematic Review and Meta-Analysis
por: Xia, Lin-Yu, et al.
Publicado: (2021)

The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis
por: Chen, Jiarong, et al.
Publicado: (2016)

6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

Methodological quality evaluation of systematic reviews or meta-analysis of trastuzumab-based therapy for breast cancer: A systematic review
por: Wei, Hua, et al.
Publicado: (2021)

Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis
por: Cobert, Amani M., et al.
Publicado: (2020)

Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis
por: Obasi, Mary, et al.
Publicado: (2021)

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
por: Liu, Xiaoyun, et al.
Publicado: (2022)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Trastuzumab administration during pregnancy: an update
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis
por: Davari, Majid, et al.
Publicado: (2017)

Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab
por: Demissei, Biniyam G., et al.
Publicado: (2020)

The Predictive and Prognostic Role of Stromal Tumor-infiltrating Lymphocytes in HER2-positive Breast Cancer with Trastuzumab-based Treatment: a Meta-analysis and Systematic Review
por: Xu, Tao, et al.
Publicado: (2017)

High Plasma Fibrinogen is Correlated With Poor Response to Trastuzumab Treatment in HER2 Positive Breast Cancer
por: Liu, Yu-Lin, et al.
Publicado: (2015)

Correction to: Trastuzumab administration during pregnancy: an update
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study
por: Guo, Zihan, et al.
Publicado: (2022)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2018)

Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
por: Genuino, Anne Julienne, et al.
Publicado: (2019)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
por: Triantafyllidi, Eleni, et al.
Publicado: (2022)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2017)

Clinical therapeutic effects of trastuzumab in HER2-positive breast cancer patients: A protocol for systematic review and meta-analysis
por: Tong, Chuanming, et al.
Publicado: (2021)

The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis
por: Jackson, Christopher, et al.
Publicado: (2022)

Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis
por: Jawa, Zeeshan, et al.
Publicado: (2016)

Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
por: Barat, Eric C., et al.
Publicado: (2023)

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
por: Clayton, A J, et al.
Publicado: (2004)

Coq10 for preventing cardiotoxicity in breast cancer patients treated with trastuzumab
por: Al-Hammadi, Nawal, et al.
Publicado: (2023)

Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials
por: Xu, Zhi-qiao, et al.
Publicado: (2017)

Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis
por: Soares, L.R., et al.
Publicado: (2023)

HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis
por: Xu, Qian-Qian, et al.
Publicado: (2016)

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
por: Wu, Yu-Tuan, et al.
Publicado: (2018)

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Safety of trastuzumab (Herceptin(®)) during pregnancy: two case reports
por: Goodyer, Matthew J, et al.
Publicado: (2009)

Prevalence of Budd-Chiari Syndrome during Pregnancy or Puerperium: A Systematic Review and Meta-Analysis
por: Ren, Weirong, et al.
Publicado: (2015)

Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis
por: Goulas, Kyriakos, et al.
Publicado: (2023)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
por: Alder, Laura, et al.
Publicado: (2023)

Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
por: Stewart, Paul, et al.
Publicado: (2020)

Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis
por: Khoirunnisa, Sudewi Mukaromah, et al.
Publicado: (2023)

Interventions to treat mental disorders during pregnancy: A systematic review and multiple treatment meta-analysis
por: van Ravesteyn, Leontien M., et al.
Publicado: (2017)

Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis
por: Bai, Xue, et al.
Publicado: (2021)

Trastuzumab Exposure in Early Pregnancy for a Young Lady With Locally Invasive Breast Cancer
por: Pianca, Natasha, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kurp413jffne690kdv68lm9nib